Skip to main content
NCBI home page
British Medical Journal logoLink to British Medical Journal
. 1975 Aug 23;3(5981):461–464. doi: 10.1136/bmj.3.5981.461

Immunopotentiation with levamisole in resectable bronchogenic carcinoma: a double-blind controlled trial; Study Group for Bronchogenic Carcinoma.

PMCID: PMC1674282  PMID: 1098727

Abstract

A long-term multicentre double-blind study was designed to test the immunotropic effects of levamisole in patients undergoing operation for primary bronchial carcinoma. They received levamisole 50 mg three times a day by mouth or placebo for three days every fortnight, starting three days before surgery. Unless there was clinical evidence of recurrence, cytostatic drugs, corticosteroids, and radiotherapy were prohibited. In the 111 patients who have been followed up for one year the incidence of side effects was similar in both groups. Recurrences occurred in 10 out of 51 patients (seven deaths) receiving levamisole and in 20 out of 60 (12 deaths) receiving placebo. Further analysis showed that there were fewer recurrences on levamisole in patients with squamous cell carcinomas and medium and large primary tumours and fewer suspected and proved recurrences and deaths from metastases on levamisole in patients with extended tumours. Distant recurrences tended to be less common with levamisole, whereas the disease-free interval in relapsing patients was almost identical in the two groups. These interim results show that levamisole seems to exert its beneficial effect by preventing immunosuppression due to surgery.

Full text

PDF
461

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Biniaminov M., Ramot B. Letter: In-vitro resotration by levamisole of thymus-derived lymphocyte function in Hodgkin's disease. Lancet. 1975 Feb 22;1(7904):464–464. doi: 10.1016/s0140-6736(75)91543-3. [DOI] [PubMed] [Google Scholar]
  2. Chirigos M. A., Pearson J. W., Pryor J. Augmentation of chemotherapeutically induced remission of a murine leukemia by a chemical immunoadjuvant. Cancer Res. 1973 Nov;33(11):2615–2618. [PubMed] [Google Scholar]
  3. Cochran A. J., Thomas C. E., Spilg W. G., Grant R. M., Cameron-Mowat D. E., Mackie R. M., Lindop G. Tumor-directed cellular immunity in malignant melanoma and its modification by surgical treatment. Yale J Biol Med. 1973 Dec;46(5):650–654. [PMC free article] [PubMed] [Google Scholar]
  4. Ducos J., Migueres J., Colombies P., Kessous A., Poujoulet N. Lymphocyte response to P.H.A. in patients with lung cancer. Lancet. 1970 May 23;1(7656):1111–1112. doi: 10.1016/s0140-6736(70)92775-3. [DOI] [PubMed] [Google Scholar]
  5. Han T. Postoperative immunosuppression in patients with breast cancer. Lancet. 1972 Apr 1;1(7753):742–743. doi: 10.1016/s0140-6736(72)90248-6. [DOI] [PubMed] [Google Scholar]
  6. Han T., Takita H. Immunologic impairment in bronchogenic carcinoma: a study of lymphocyte response to phytohemagglutinin. Cancer. 1972 Sep;30(3):616–620. doi: 10.1002/1097-0142(197209)30:3<616::aid-cncr2820300304>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
  7. Israel L., Mugica J., Chahinian P. Prognosis of early bronchogenic carcinoma. Survival curves of 451 patients after resection of lung cancer in relation to the results of pre-operative tuberculin skin test. Biomedicine. 1973 Feb 10;19(2):68–72. [PubMed] [Google Scholar]
  8. Krant M. J., Manskopf G., Brandrup C. S., Madoff M. A. Immunologic alterations in bronchogenic cancer. Sequential study. Cancer. 1968 Apr;21(4):623–631. doi: 10.1002/1097-0142(196804)21:4<623::aid-cncr2820210414>3.0.co;2-p. [DOI] [PubMed] [Google Scholar]
  9. Slack N. H. Bronchogenic carcinoma: nitrogen mustard as a surgical adjuvant and factors influencing survival. University surgical adjuvant lung project. Cancer. 1970 May;25(5):987–1002. doi: 10.1002/1097-0142(197005)25:5<987::aid-cncr2820250502>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  10. Tripodi D., Parks L. C., Brugmans J. Drug-induced restoration of cutaneous delayed hypersensitivity in anergic patients with cancer. N Engl J Med. 1973 Aug 16;289(7):354–357. doi: 10.1056/NEJM197308162890707. [DOI] [PubMed] [Google Scholar]
  11. Vaage J. Influence of tumor antigen on maintenance versus depression of tumor-specific immunity. Cancer Res. 1973 Mar;33(3):493–503. [PubMed] [Google Scholar]
  12. Verhaegen H., De Cock W., De Cree J., Verbruggen F., Verhaegen-Declercq M., Brugmans J. Letter: In-vitro restoration by levamisole of thymus-derived lymphocyte functions in Hodgkin's disease. Lancet. 1975 Apr 26;1(7913):978–978. doi: 10.1016/s0140-6736(75)92040-1. [DOI] [PubMed] [Google Scholar]
  13. Watson R. D., Smith A. G., Levy J. G. The use of immunoadsorbent columns for the isolation of antibodies specific for antigens associated with human bronchogenic carcinoma. Br J Cancer. 1974 Mar;29(3):183–188. doi: 10.1038/bjc.1974.57. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES